Hepatocellular carcinoma resistance to tyrosine kinase inhibitors: Current status and perspectives

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=63

Apr 15, 2025 (publication date) through Mar 25, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 101528
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.101528

Table 1 Advances in hepatocellular carcinoma drug combinations

Drug combination	Drugs
Combinations of molecular-targeted drugs	PKI-587 + Sorafenib
Combinations of molecular-targeted drugs	Sorafenib + Dasatinib
Combinations of immunotherapy drugs	Atezolizumab + Bevacizumab
	Pembrolizumab + Lenvatinib
	Cabozantinib + Nivolumab
Combinations of natural medicines	Celastrol + Sorafenib
Combinations of natural medicines	Bufalin + Sorafenib

Citation: Miao YR, Yang XJ. Hepatocellular carcinoma resistance to tyrosine kinase inhibitors: Current status and perspectives. World J Gastrointest Oncol 2025; 17(4): 101528
URL: https://www.wjgnet.com/1948-5204/full/v17/i4/101528.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.101528